siRNA‐based nanotherapeutics as emerging modalities for immune‐mediated diseases: A preliminary review

Saman Sargazi; Rabia Arshad; Reza GhamariAbbas RahdarAli BakhshiSonia Fathi KarkanNarges AjalliMuhammad BilalAna M. Díez‐Pascual

首页> 外文期刊>Cell biology international. >siRNA‐based nanotherapeutics as emerging modalities for immune‐mediated diseases: A preliminary review

【24h】

siRNA‐based nanotherapeutics as emerging modalities for immune‐mediated diseases: A preliminary review

机译：siRNA‐based nanotherapeutics as emerging modalities for immune‐mediated diseases: A preliminary review

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Abstract Immune‐mediated diseases (IMDs) are chronic conditions that have an immune‐mediated etiology. Clinically, these diseases appear to be unrelated, but pathogenic pathways have been shown to connect them. While inflammation is a common occurrence in the body, it may either stimulate a favorable immune response to protect against harmful signals or cause illness by damaging cells and tissues. Nanomedicine has tremendous promise for regulating inflammation and treating IMIDs. Various nanoparticles coated with nanotherapeutics have been recently fabricated for effective targeted delivery to inflammatory tissues. RNA interference (RNAi) offers a tremendous genetic approach, particularly if traditional treatments are ineffective against IMDs. In cells, several signaling pathways can be suppressed by using RNAi, which blocks the expression of particular messenger RNAs. Using this molecular approach, the undesirable effects of anti‐inflammatory medications can be reduced. Still, there are many problems with using short‐interfering RNAs (siRNAs) to treat IMDs, including poor localization of the siRNAs in target tissues, unstable gene expression, and quick removal from the blood. Nanotherapeutics have been widely used in designing siRNA‐based carriers because of the restricted therapy options for IMIDs. In this review, we have discussed recent trends in the fabrication of siRNA nanodelivery systems, including lipid‐based siRNA nanocarriers, liposomes, and cationic lipids, stable nucleic acid‐lipid particles, polymeric‐based siRNA nanocarriers, polyethylenimine (PEI)‐based nanosystems, chitosan‐based nanoformulations, inorganic material‐based siRNA nanocarriers, and hybrid‐based delivery systems. We have also introduced novel siRNA‐based nanocarriers to control IMIDs, such as pulmonary inflammation, psoriasis, inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, etc. This study will pave the way for new avenues of research into the diagnosis and treatment of IMDs.

著录项

来源
《Cell biology international.》 |2022年第9期|1320-1344|共25页
作者
Saman Sargazi; Rabia Arshad; Reza GhamariAbbas RahdarAli BakhshiSonia Fathi KarkanNarges AjalliMuhammad BilalAna M. Díez‐Pascual;
展开▼
作者单位

Cellular and Molecular Research Center,Research Institute of Cellular and Molecular Sciences in;

Department of Pharmacy,Quaid‐i‐Azam University Islamabad;

Department of Biotechnology,National Institute of Genetic Engineering and BiotechnologyDepartment of Physics,University of ZabolSchool of Physics,Institute for Research in Fundamental Sciences (IPM)Student Research Committee,Tabriz University of Medical SciencesDepartment of Chemical Engineering, Faculty of Engineering,University of TehranSchool of Life Science and Food Engineering,Huaiyin Institute of TechnologyUniversidad de Alcalá, Facultad de Ciencias, Departamento de Quimica Analítica,Química Física e;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类细胞生物学;
关键词
autoimmunity; drug delivery; inflammation; nanotechnology; nanotherapeutics; siRNA;

siRNA‐based nanotherapeutics as emerging modalities for immune‐mediated diseases: A preliminary review

摘要

著录项

相关主题

期刊订阅